Academic Journal
Nephrolithiasis in Cystic Fibrosis: A Gastrointestinal Perspective on Mechanisms and Management.
| Τίτλος: | Nephrolithiasis in Cystic Fibrosis: A Gastrointestinal Perspective on Mechanisms and Management. |
|---|---|
| Συγγραφείς: | Wilder A; Saint Louis University School of Medicine, St. Louis, Missouri, USA., Schindler T; University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Saikumar P; Pediatric Gastroenterology, Hepatology and Nutrition, Mary Bridge Children's Hospital, Tacoma, Washington, USA., Patel D; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cardinal Glennon Children's Medical Center, Saint Louis University School of Medicine, St Louis, Missouri, USA., Sankararaman S; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA. |
| Πηγή: | Pediatric pulmonology [Pediatr Pulmonol] 2026 Oct; Vol. 61 (10), pp. e71848. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8510590 Publication Model: Print Cited Medium: Internet ISSN: 1099-0496 (Electronic) Linking ISSN: 10990496 NLM ISO Abbreviation: Pediatr Pulmonol Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2005-> : Hoboken, NJ : Wiley-Liss Original Publication: [Philadelphia, PA] : W.B. Saunders, [c1985- |
| Ιατρικοί όροι (MeSH): | Cystic Fibrosis*/complications , Nephrolithiasis*/etiology , Nephrolithiasis*/therapy , Nephrolithiasis*/epidemiology, Humans ; Child |
| Περίληψη: | In the current era of cystic fibrosis (CF) transmembrane conductance regulator (CFTR)-directed therapies (modulators), people with CF have significant improvement in pulmonary disease burden and overall survival. Extrapulmonary complications, including those affecting the gastrointestinal and renal systems, are gaining attention. Nephrolithiasis is increasingly recognized as a significant comorbidity in CF. The mechanisms underlying nephrolithiasis in CF are multifactorial and closely associated with altered gastrointestinal milieu in CF. Overt or residual fat malabsorption (due to exocrine pancreatic insufficiency along with other causes such as altered bile salt handling, acidic intestinal pH), and increased intestinal permeability collectively enhance enteric oxalate absorption. Renal stones in CF tend to present at a younger age, are associated with higher recurrence rates, and require more frequent procedural interventions compared with the general population with nephrolithiasis. With the increased survival in the post modulator era, the burden of renal complications in CF is expected to grow. There is lack of CF-specific nephrolithiasis guidelines and more studies on this topic are needed. Also, given the paucity of pediatric studies, literature from adults can be carefully inferred. Clinicians should educate people with CF on preventative strategies such as optimizing pancreatic enzyme replacement therapy, enhancing hydration, nutritional management strategies such as optimizing dietary calcium intake particularly when consuming high-oxalate foods, managing hypocitraturia, and minimization of nephrotoxic medication exposures. Multidisciplinary team approach is recommended to optimize outcomes from nephrolithiasis. In this review, the epidemiology, pathogenic mechanisms, and clinical management of nephrolithiasis in CF, with an emphasis on early-life contributors and opportunities for improved prevention in CF management are detailed. (© 2026 Wiley Periodicals LLC.) |
| References: | S. M. Rowe, S. Miller, and E. J. Sorscher, “Cystic Fibrosis,” New England Journal of Medicine 352 (2005): 1992–2001. O. Adeyemo‐Salami, “Cystic Fibrosis in the Intestine and the Influence on Digestion,” Journal of Immunological Sciences 4, no. 3 (2020): 22–32. J. S. Elborn, “Cystic Fibrosis,” The Lancet 388, no. 10059 (2016): 2519–2531. P.‐R. Burgel, K. W. Southern, C. Addy, et al., “Standards for the Care of People With Cystic Fibrosis (CF); Recognising and Addressing CF Health Issues,” Journal of Cystic Fibrosis 23, no. 2 (2024): 187–202. M. J. Wilcock, A. Ruddick, K. M. Gyi, and M. E. Hodson, “Renal Diseases in Adults With Cystic Fibrosis: A 40 Year Single Centre Experience,” Journal of Nephrology 28, no. 5 (2015): 585–591. M. C. Florescu, E. Lyden, P. J. Murphy, D. F. Florescu, and J. Fillaus, “Long‐Term Effect of Chronic Intravenous and Inhaled Nephrotoxic Antibiotic Treatment on the Renal Function of Patients With Cystic Fibrosis,” Hemodialysis International 16, no. 3 (2012): 414–419. M. Hart, M. Kumar, H. B. Goswami, W. T. Harris, S. Skopelja‐Gardner, and A. Swiatecka‐Urban, “Cystic Fibrosis–Related Kidney Disease—Emerging Morbidity and Disease Modifier,” Pediatric Nephrology 40, no. 12 (2025): 3605–3614. J. Moryousef, J. Kwong, T. Kishibe, and M. Ordon, “Systematic Review of the Prevalence of Kidney Stones in Cystic Fibrosis,” Journal of Endourology 35, no. 11 (2021): 1693–1700. C. Y. Ooi and P. R. Durie, “Cystic Fibrosis From the Gastroenterologist's Perspective,” Nature Reviews Gastroenterology and Hepatology 9, no. 3 (2012): 175–185. M. Hatch and R. W. Freel, “The Roles and Mechanisms of Intestinal Oxalate Transport in Oxalate Homeostasis,” Seminars in Nephrology 28, no. 2 (2008): 143–151. B. Hoppe, A. Hesse, S. Brömme, E. Rietschel, and D. Michalk, “Urinary Excretion Substances in Patients With Cystic Fibrosis: Risk of Urolithiasis?,” Pediatric Nephrology 12, no. 4 (1998): 275–279. G. E. Tasian and L. Copelovitch, “Evaluation and Medical Management of Kidney Stones in Children,” Journal of Urology 192, no. 4 (2014): 1329–1336. D. Assimos, A. Krambeck, N. L. Miller, et al., “Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II,” Journal of Urology 196, no. 4 (2016): 1161–1169. D. Borowitz, R. D. Baker, and V. Stallings, “Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,” Journal of Pediatrics 140, no. 2 (2002): 156–164. C. Castellani, A. J. A. Duff, S. C. Bell, et al., “ECFS Best Practice Guidelines: The 2018 Revision,” Journal of Cystic Fibrosis 17, no. 2 (2018): 153–178. R. Arya, I. Sharpe, S. Y. Cheng, et al., “Elevated Rates and Earlier Onset of Nonpulmonary Comorbidities in Adults With Cystic Fibrosis,” Annals of the American Thoracic Society 22, no. 12 (2025): 1874–1880. M. S. Stalvey, J. Pace, M. Niknian, et al., “Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor,” Pediatrics 139, no. 2 (2017): e20162522. P. Gabai, E. Novel‐Catin, Q. Reynaud, et al., “Kidney Effects of Triple CFTR Modulator Therapy in People With Cystic Fibrosis,” Clinical Kidney Journal 17, no. 10 (2024): sfae256. G. U. Collaborators, “The Global, Regional, and National Burden of Urolithiasis in 204 Countries and Territories, 2000‐2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” EClinicalMedicine 78 (2024): 102924. E. M. Gibney and D. S. Goldfarb, “The Association of Nephrolithiasis With Cystic Fibrosis,” American Journal of Kidney Diseases 42, no. 1 (2003): 1–11. M. R. Perez‐Brayfield, D. Caplan, and J. M. Gatti, “Metabolic Risk Factors for Stone Formation in Cystic Fibrosis,” Journal of Urology 167, no. 2 (2002): 480–484. D. Y. Ryoo, N. Ladd, S. Culp, et al., “Prevalence and Risk Factors for Nephrolithiasis in Adults With Cystic Fibrosis: A Retrospective Cohort Study,” PLoS One 21, no. 1 (2026): e0340293. J. F. Wright, W. Y. Craig, F. L. Lucas, D. S. Goldfarb, J. B. Zuckerman, and E. N. Taylor, “Urinary Stone Disease Prevalence and Associations in Cystic Fibrosis,” Urolithiasis 49, no. 5 (2021): 415–423. F. Cystic Fibrosis, Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report (Cystic Fibrosis Foundation, 2024). CFF. Annual Data Report 2024 Cystic Fibrosis Foundation Patient Registry. https://www.cff.org/medical‐professionals/patient‐registry. 2024. B. P. O'Sullivan, D. Baker, K. G. Leung, G. Reed, S. S. Baker, and D. Borowitz, “Evolution of Pancreatic Function During the First Year in Infants With Cystic Fibrosis,” The Journal of Pediatrics 162, no. 4 (2013): 808–812.e1. S. A. McColley, S. L. Martiniano, C. L. Ren, et al., “Disparities in First Evaluation of Infants With Cystic Fibrosis Since Implementation of Newborn Screening,” Journal of Cystic Fibrosis 22, no. 1 (2023): 89–97. J. G. Young, “Urinary Tract Stones in Cystic Fibrosis,” Paediatric Respiratory Reviews 27 (2018): 21–23. P. Asfuroglu and A. Asfuroglu, “Urinary System Involvement in Children With Cystic Fibrosis: A Single‐Center Retrospective Cohort,” Pediatric Pulmonology 61, no. 3 (2026): e71551. S. Chen, X. Ma, L. Guo, et al., “The Global, Regional, and National Burden of Pediatric Stone Disease: 1990–2021 and Projections for the Next Two Decades,” Frontiers in Pediatrics 13 (2025): 1529407. L. Hu, K. He, L. Jin, and X. Yan, “Metabolic Evaluation and Disease Characteristics of Urolithiasis in Children From 2020 to 2024: a Retrospective Single‐Center Study at the National Children's Medical Center,” BMC Pediatrics 25, no. 1 (2025): 505. M. Terribile, M. Capuano, G. Cangiano, et al., “Factors Increasing the Risk for Stone Formation in Adult Patients With Cystic Fibrosis,” Nephrology Dialysis Transplantation 21, no. 7 (2006): 1870–1875. R. Heiden, A. P. G. Balestra, M. G. Bianchetti, et al., “Which Factors Account for Renal Stone Formation in Cystic Fibrosis?,” Clinical Nephrology 59, no. 3 (2003): 160–163. A. Horsley, J. Helm, A. Brennan, R. Bright‐Thomas, K. Webb, and A. Jones, “Gout and Hyperuricaemia in Adults With Cystic Fibrosis,” Journal of the Royal Society of Medicine 104, no. 1_suppl (2011): 36–39. F. B. Stapleton, J. Kennedy, S. Nousia‐Arvanitakis, and M. A. Linshaw, “Hyperuricosuria Due to High‐Dose Pancreatic Extract Therapy in Cystic Fibrosis,” New England Journal of Medicine 295, no. 5 (1976): 246–248. S. Wiersbitzky, E. H. Ballke, E. Wolf, and W. Paul, “Uric Acid Serum Concentrations in CF‐Children After Pancreatic Enzyme Supplementation,” Padiatrie und Grenzgebiete 28, no. 3 (1989): 171–173. M. A. Turner, “Oxalate and Calcium Excretion in Cystic Fibrosis,” Archives of Disease in Childhood 83, no. 3 (2000): 244–247. J. L. Fridge, C. Conrad, L. Gerson, R. O. Castillo, and K. Cox, “Risk Factors for Small Bowel Bacterial Overgrowth in Cystic Fibrosis,” Journal of Pediatric Gastroenterology and Nutrition 44, no. 2 (2007): 212–218. J. Dorsey and T. Gonska, “Bacterial Overgrowth, Dysbiosis, Inflammation, and Dysmotility in the Cystic Fibrosis Intestine,” Journal of Cystic Fibrosis 16 (2017): S14–S23. J. W. Dobbins and H. J. Binder, “Effect of Bile Salts and Fatty Acids on the Colonic Absorption of Oxalate,” Gastroenterology 70, no. 6 (1976): 1096–1100. C. Witting, C. B. Langman, D. Assimos, et al., “Pathophysiology and Treatment of Enteric Hyperoxaluria,” Clinical Journal of the American Society of Nephrology 16, no. 3 (2021): 487–495. J. Desenclos, V. Forté, C. Clément, M. Daudon, and E. Letavernier, “Pathophysiology and Management of Enteric Hyperoxaluria,” Clinics and Research in Hepatology and Gastroenterology 48, no. 5 (2024): 102322. P. Varanasi, A. A. Yau, and M. Keddis, “Gut to Stone: The Woes of Malabsorption and Kidney Stone Growth,” Kidney International Reports 10, no. 7 (2025): 3678–3680. M. Rudziński, M. Ławiński, Ł. Gradowski, et al., “Kidney Stones are Common in Patients With Short‐Bowel Syndrome Receiving Long‐Term Parenteral Nutrition: A Predictive Model for Urolithiasis,” Journal of Parenteral and Enteral Nutrition 46, no. 3 (2022): 671–677. M. Vujasinovic, A. Dugic, T. Thiel, A. Kjellman, C. Yang, and J. M. Löhr, “Pancreatic Exocrine Insufficiency is a Risk Factor for Kidney Stones in Patients With Chronic Pancreatitis,” Pancreatology 23, no. 3 (2023): 294–298. C.‐H. Chen, C.‐L. Lin, and L.‐B. Jeng, “Association Between Chronic Pancreatitis and Urolithiasis: A Population‐Based Cohort Study,” PLoS One 13, no. 3 (2018): e0194019. H. Böhles, B. Gebhardt, T. Beeg, A. C. Sewell, E. Solem, and G. Posselt, “Antibiotic Treatment‐Induced Tubular Dysfunction as a Risk Factor for Renal Stone Formation in Cystic Fibrosis,” The Journal of Pediatrics 140, no. 1 (2002): 103–109. F. Knauf, R. B. Thomson, J. F. Heneghan, et al., “Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion,” Journal of the American Society of Nephrology 28, no. 1 (2017): 242–249. R. D. Mittal, R. Kumar, B. Mittal, R. Prasad, and M. Bhandari, “Stone Composition, Metabolic Profile and the Presence of the Gut‐Inhabiting Bacterium Oxalobacter formigenes as Risk Factors for Renal Stone Formation,” Medical Principles and Practice 12, no. 4 (2003): 208–213. R. Kumar, U. C. Ghoshal, G. Singh, and R. D. Mittal, “Infrequency of Colonization With Oxalobacter Formigenes in Inflammatory Bowel Disease: Possible Role in Renal Stone Formation,” Journal of Gastroenterology and Hepatology 19, no. 12 (2004): 1403–1409. Y. Ravikumar, R. F. Begum, and R. Velmurugan, “Oxalobacter Formigenes Reduce the Risk of Kidney Stones in Patients Exposed to Oral Antibiotics: A Case–Control Study,” International Urology and Nephrology 53, no. 1 (2021): 13–20. S. Fargue, M. Suryavanshi, K. D. Wood, et al., “Inducing Oxalobacter Formigenes Colonization Reduces Urinary Oxalate in Healthy Adults,” Kidney International Reports 10, no. 5 (2025): 1518–1528. H. Sidhu, B. Hoppe, A. Hesse, et al., “Absence of Oxalobacter Formigenes in Cystic Fibrosis Patients: A Risk Factor for Hyperoxaluria,” The Lancet 352, no. 9133 (1998): 1026–1029. A. Niknahad, L. Shahkar, F. Kompani, M. Montazeri, and A. A. Ahani Comparative Study of Urinary Minerals and Their Effect on Stone Formation in Two Groups of Cystic Fibrosis (CF) and Healthy Children. 2020. B. Hoppe, G. E. von Unruh, G. Blank, et al., “Absorptive Hyperoxaluria Leads to an Increased Risk for Urolithiasis or Nephrocalcinosis in Cystic Fibrosis,” American Journal of Kidney Diseases 46, no. 3 (2005): 440–445. A. Andrieux, J. Harambat, S. Bui, et al., “Renal Impairment in Children With Cystic Fibrosis,” Journal of Cystic Fibrosis 9, no. 4 (2010): 263–268. P. Skrzypczyk and M. Pańczyk‐Tomaszewska, “Hypocitraturia: Its Importance as a Factor in the Development of Urolithiasis,” Paediatrics and Family Medicine 15, no. 1 (2019): 26. C. Schott, A. Pourtousi, and D. M. Connaughton, “Monogenic Causation of Pediatric Nephrolithiasis,” Frontiers in Urology 2 (2022): 1075711. C. M. Carmen Tong, J. S. Ellison, and G. E. Tasian, “Pediatric Stone Disease,” Urologic Clinics of North America 50, no. 3 (2023): 465–475. A. Skolarikos, R. Geraghty, B. Somani, et al., European Association of Urology Guidelines on the Diagnosis and Treatment of Urolithiasis (Elsevier, 2025). 88, 64–75. T. Hughes, H. C. Ho, A. Pietropaolo, and B. K. Somani, “Guideline of Guidelines for Kidney and Bladder Stones,” Urology Research and Practice 46, no. Suppl 1 (2020): S104–S112. M. Bargagli, M. Scoglio, S. A. Howles, and D. G. Fuster, “Kidney Stone Disease: Risk Factors, Pathophysiology and Management,” Nature Reviews Nephrology 21, no. 11 (2025): 794–808. B. Cao, R. Daniel, R. McGregor, and G. E. Tasian, “Pediatric Nephrolithiasis,” Healthcare 11, no. 4 (2023): 552. S. Koletzko and D. Reinhardt, “Nutritional Challenges of Infants With Cystic Fibrosis,” Early Human Development 65 (2001): S53–S61. M. Wilschanski, A. Munck, E. Carrion, et al., “ESPEN‐ESPGHAN‐ECFS Guideline on Nutrition Care for Cystic Fibrosis,” Clinical Nutrition 43, no. 2 (2024): 413–445. S. Güven, T. Tokas, A. Tozsin, et al., “Consensus Statement Addressing Controversies and Guidelines on Pediatric Urolithiasis,” World Journal of Urology 42, no. 1 (2024): 473. K. L. Penniston and S. Y. Nakada, “Diet and Alternative Therapies in the Management of Stone Disease,” Urologic Clinics of North America 40, no. 1 (2013): 31–46. L. K. Massey, H. Roman‐Smith, and R. A. Sutton, “Effect of Dietary Oxalate and Calcium on Urinary Oxalate and Risk of Formation of Calcium Oxalate Kidney Stones,” Journal of the American Dietetic Association 93, no. 8 (1993): 901–906. M. S. Pearle, D. S. Goldfarb, D. G. Assimos, et al., “Medical Management of Kidney Stones: AUA Guideline,” Journal of Urology 192, no. 2 (2014): 316–324. E. T. Zemanick, J. L. Taylor‐Cousar, J. Davies, et al., “A Phase 3 Open‐Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age With Cystic Fibrosis and at Least One F508del Allele,” American Journal of Respiratory and Critical Care Medicine 203, no. 12 (2021): 1522–1532. M. D. Sorensen, “Calcium Intake and Urinary Stone Disease,” Translational Andrology and Urology 3, no. 3 (2014): 235–240. C. Y. Pak, “Citrate and Renal Calculi,” Mineral and Electrolyte Metabolism 12 (1986): 113–119. Y. Bao, X. Tu, and Q. Wei, “Water for Preventing Urinary Stones,” Cochrane Database of Systematic Reviews 2, no. 2 (2020): CD004292. https://doi.org/10.1002/14651858.CD004292.pub4. M. S. Pearle, B. R. Matlaga, J. A. Antonelli, et al., “Medical Management of Kidney Stones: AUA Guideline (2026) Part I: Evaluation of Patients With Kidney Stones and Dietary Management of Patients With Calcium Stones,” Journal of Urology [Internet]. https://doi.org/10.1097/JU.0000000000005227. S. K. Ranjan, A. Mittal, A. A. Mirza, et al., “Metabolic Evaluation of First‐Time Uncomplicated Renal Stone Formers: A Prospective Study,” Current Urology 17, no. 1 (2023): 36–40. A. Smyth, K. H. Tan, and P. Hyman‐Taylor, “Once‐Daily Versus Multiple‐Daily Dosing of Aminoglycosides in Cystic Fibrosis,” Thorax 68, no. 4 (2013): 356–364. M. Riccabona, M. L. Lobo, F. Papadopoulou, et al., “ESPR Uroradiology Task Force and ESUR Paediatric Working Group: Imaging Recommendations in Paediatric Uroradiology, Part IV: Minutes of the ESPR Uroradiology Task Force Mini‐Symposium on Imaging in Childhood Renal Hypertension and Imaging of Renal Trauma in Children,” Pediatric Radiology 41, no. 7 (2011): 939–944. R. M. Geraghty, N. F. Davis, L. Tzelves, et al., “Best Practice in Interventional Management of Urolithiasis: An Update From the European Association of Urology Guidelines Panel for Urolithiasis 2022,” European Urology Focus 9, no. 1 (2023): 199–208. G. E. Tasian, D. I. Chu, C. P. Nelson, et al., “Ureteroscopy vs Shockwave Lithotripsy to Remove Kidney Stones in Children and Adolescents: A Nonrandomized Clinical Trial,” JAMA Network Open 8, no. 8 (2025): e2525789. F. Frost, P. Griffiths, C. Brockelsby, C. Lynch, M. J. Walshaw, and D. Nazareth, “Between a Rock and an Airspace: Pneumothorax After Extracorporeal Shock Wave Lithotripsy for Renal Stones in a Patient With Cystic Fibrosis,” Chest 154, no. 3 (2018): 61. S. Romano, T. Frantzen, G. LaVecchia, and J. Wang, “188: Cystic Fibrosis Kidney Stone Disease in the Era of CFTR Modulator Use and the COVID‐19 Pandemic,” Journal of Cystic Fibrosis 20 (2021): S92–S93. L. An, S. Li, Z. Chang, et al., “Gut Microbiota Modulation via Fecal Microbiota Transplantation Mitigates Hyperoxaluria and Calcium Oxalate Crystal Depositions Induced by High Oxalate Diet,” Gut Microbes 17, no. 1 (2025): 2457490. Y. Zhou, M. Lei, W. Cai, et al., “Human Fecal Microbiota Transplantation Attenuates High Dietary Oxalate‐Induced Renal Calcium Oxalate Crystal Depositions in Rats via Repairing Allobaculum‐Related Gut Barrier Damage,” mSystems 10, no. 9 (2025): e0081025. ClinicalTrials.gov. Fecal Microbiota Transplantation in Kidney Stone Patients. 2025. J. C. Lieske, J. E. Lingeman, P. M. Ferraro, et al., “Randomized Placebo‐Controlled Trial of Reloxaliase in Enteric Hyperoxaluria,” NEJM Evidence 1, no. 7 (2022): EVIDoa2100053. J. C. Lieske, D. S. Goldfarb, C. De Simone, and C. Regnier, “Use of a Probioitic to Decrease Enteric Hyperoxaluria,” Kidney International 68, no. 3 (2005): 1244–1249. H. Yavuz, M. Kumar, H. B. Goswami, et al., “Diagnosis and Emerging Biomarkers of Cystic Fibrosis‐Related Kidney Disease (CFKD),” Journal of Clinical Medicine 14, no. 15 (2025): 5585. |
| Contributed Indexing: | Keywords: CF; cystic fibrosis; nephrolithiasis; oxalate; renal stones |
| Entry Date(s): | Date Created: 20260928 Date Completed: 20260928 Latest Revision: 20260928 |
| Update Code: | 20260928 |
| DOI: | 10.1002/ppul.71848 |
| PMID: | 42803148 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!